Human Immunome Project (HIP) Company Profile

Background

The Human Immunome Project (HIP) is a global nonprofit organization dedicated to decoding and modeling the human immune system to improve health worldwide. Established in 2016 as the Human Vaccines Project, HIP has evolved to leverage advanced immunological data and artificial intelligence (AI) to transform health outcomes. The organization's mission is to generate the world's largest and most comprehensive immunological dataset and build publicly available AI models of the immune system.

Key Strategic Focus

HIP's strategic focus centers on:

Data Generation: Establishing a global network of study sites to collect extensive, high-resolution immunological data from diverse populations.

AI Model Development: Utilizing the collected data to develop predictive and mechanistic AI models of the immune system, aiming to accelerate medical research and drug discovery.

Global Collaboration: Partnering with research institutions, industry leaders, and governments to ensure the dataset reflects humanity's diversity and to promote health equity.

Financials and Funding

HIP has received support from various organizations, including a grant from the Bill & Melinda Gates Foundation in October 2022 to develop a globally equitable roadmap for an AI model of the human immunome. Additionally, partnerships with companies like Danaher Corporation provide HIP with access to essential research tools and technologies.

Pipeline Development

HIP's primary initiative involves a phased approach:

Phase I: Establishing pilot sites to collect high-resolution immunological data from approximately 1,500 participants over five years.

Phase II: Scaling data collection to 150 study sites globally, focusing on diverse populations to build a comprehensive dataset.

Phase III: Developing advanced AI models to predict immune responses and health trajectories, facilitating the discovery of new medical targets and interventions.

Technological Platform and Innovation

HIP distinguishes itself through:

Immune Monitoring Kits (IM-Kits): Engineered to capture standardized, multi-omic data efficiently, enabling large-scale data collection.

AI-Driven Analysis: Employing machine learning algorithms to integrate various biological data types, capturing immune system dynamics and predicting individual responses to perturbations.

Leadership Team

Jane Metcalfe: Executive Chair. Assumed the role in May 2025, transitioning from Board Chair to lead HIP's operational launch.

Dr. Hans Keirstead: Board Member. Served as CEO from 2023 to May 2025, overseeing the development of HIP's operational and strategic plans.

Dr. Shai Shen-Orr: Co-Chief Science Officer. Professor at the Technion Israel Institute of Technology, specializing in systems immunology and precision medicine.

Dr. John Tsang: Co-Chief Science Officer. Professor of Immunobiology and Biomedical Engineering at Yale University, focusing on systems immunology and computational biology.

Leadership Changes

In May 2025, HIP announced a leadership transition with Jane Metcalfe becoming Executive Chair, succeeding Dr. Hans Keirstead, who concluded his two-year term as CEO and remains an active Board member.

Competitor Profile

Market Insights and Dynamics

The field of immunological research is experiencing significant growth, driven by advancements in AI and data analytics. The global immunology market is expanding, with increasing investments in understanding immune system dynamics to develop targeted therapies and diagnostics.

Competitor Analysis

Key competitors include:

The Immunological Genome Project (ImmGen): Focuses on characterizing the mouse immunome to provide insights into gene expression and regulation within the immune system.

The Human Vaccines Project: Aims to accelerate the development of vaccines and immunotherapies by decoding the human immune system.

Immunome, Inc.: A biotechnology company specializing in the development of native human cancer antibodies targeted against cancer antigens.

Strategic Collaborations and Partnerships

HIP collaborates with various organizations to enhance its capabilities:

Danaher Corporation: Subsidiaries like Beckman Coulter Life Sciences, Abcam, and SCIEX provide HIP with access to reagents, assays, and equipment essential for data collection and analysis.

Michelson Medical Research Foundation: Partners with HIP to award the Michelson Prizes, supporting early-career scientists in immunology and vaccine research.

Operational Insights

HIP's strategic considerations include:

Global Representation: Committing to establishing 75% of study sites in low- and middle-income countries to ensure the dataset reflects global diversity.

Data Accessibility: Ensuring HIP-generated data and models are publicly available to all stakeholders, promoting transparency and collaboration.

Strategic Opportunities and Future Directions

HIP's roadmap includes:

Advancing AI Models: Developing comprehensive models to predict immune responses and health trajectories, facilitating personalized medicine.

Expanding Collaborations: Building partnerships with research institutions and industry leaders to enhance data collection and analysis capabilities.